Eighteen Fifty Equity Inc. Engages Gunpowder Capital Corp.

Toronto, Ontario–(Newsfile Corp. – February 7, 2019) – Gunpowder Capital Corp. (CSE: GPC) (CSE: GPC.PR.A) (OTCQB: GNPWF) (FSE: YS6N) (“Gunpowder” or the “Corporation”) announced today that Eighteen Fifty Equity, Inc. (“1850”), has retained Gunpowder to act as financial advisor to 1850 and to assist 1850 in completing its proposed “go public” transaction. Through its fully owned subsidiary, Natural Wellness, Inc., 1850 specializes in finding natural wellness through plant-based medicine as the Company offers a wide range of CBD products to its clientele.

Effective immediately, 1850 shall issue GPC One Million Five Hundred Thirty Thousand (“1,530,000”) common shares of 1850 and 1850 shall also pay GPC a one-time advisory fee of Twenty Thousand Dollars (“$20,000.00”) CDN plus HST for the advisory services GPC shall provide 1850 in its going public endeavors. Furthermore, and upon successful listing onto a Canadian-based stock exchange, and as compensation for GPC’s services, 1850 will issue Four Hundred and Fifty Thousand Dollars (“$450,000.00”) CDN plus HST worth of common shares in 1850 to GPC on the same terms and enterprise value as those anticipated in the going public transaction.

1850 has provided audited financials as required under the agreement, as well as being tasked with providing quarterly financials and associated MD&A. Once completed, GPC shall issue Two Hundred Thousand Dollars (“$200,000.00”) CDN worth of GPC Class – A preferred shares to 1850.

Mr. Paul Haber, Chief Financial Officer of Gunpowder, stated: “We are extremely pleased to have been selected by 1850 for this go public assignment. Gunpowder is finding a lot of private North American based Cannabis / Hemp companies that want to rapidly expand and take the next step in their business evolution which is accessing capital via the public and equity markets. Currently in this point in time, Canada offers several stock exchanges that allow Cannabis entities to list which facilitates the aforementioned need. 1850 is one such Company and we are looking forward to working with them.”

Mr. Mike Arnold of Kansas City, Missouri, CEO of 1850, stated: “We are very excited to partner with Gunpowder in our proposed ‘go public’ endeavour. We see this firm as a very unique partner as they can facilitate all of our ‘go public’ needs including providing assistance to accessing capital. We see Gunpowder as partner that will be instrumental in providing us the necessary tools so we can take the next step in our Midwest cannabis and hemp business evolution.”

Eighteen Fifty Equity Inc.

Eighteen Fifty Equity, Inc. specializes in finding natural wellness through plant-based medicine. Through its wholly owned subsidiary, Natural Wellness, Inc., (“NWI”) which was founded in Kansas City, Missouri, by Jessica Anderson, 1850 offers a wide range of CBD products to its clientele. Currently, NWI is positioning itself so it can greatly expand its market presence throughout the State of Missouri and beyond. For more information on Eighteen Fifty Equity, Inc., please visit www.1850equity.com

About Gunpowder Capital Corp.

Gunpowder Capital Corp. is a merchant bank and advisory services firm based in Toronto, Ontario, Canada. Gunpowder invests in both publicly traded and private businesses that have successful management teams and attractive economic models. Gunpowder partners with these businesses to support their growth initiatives with its proven methodology of appropriate financing and structured exits. Gunpowder offers debt financing, including mezzanine and bridge loans, equity financing and advisory services. Gunpowder is also building a portfolio of companies in which it takes a long term position and view. For more information please visit www.gunpowdercapitalcorp.com

For further information please contact:

Mr. Frank Kordy
CEO & Director
Gunpowder Capital Corp.
T: (647) 466-4037
E: frank.kordy@gunpowdercapitalcorp.com

Mr. Paul Haber
CFO
Gunpowder Capital Corp.
T: (416) 363-3833
E: paul.haber@gunpowdercapitalcorp.com

Forward-Looking Statements
Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/42690

Advertisements

Resinco Capital Partners Announces the Appointment of Sir Marc Feldmann to Advisory Board

Vancouver, British Columbia–(Newsfile Corp. – February 6, 2019) – Resinco Capital Partners Inc. (CSE: RIN) (OTC Pink: RSCZF) (FSE: L6V1) (the “Company” or “Resinco“) is pleased to announce that the Company has appointed pioneer and trailblazer of modern immunology, Sir Marc Feldmann, to its Advisory Board after fully acquiring his company, ReFormation Pharmaceuticals Corp, a medical cannabis company developing innovative, first-in-class therapies to repair vital organs and stem cells by combining cannabinoids and an endogenous trigger of repair.

Sir Marc Feldmann, whose research breakthrough on inflammation led to the creation of some of the world’s top-selling drugs like Humira and Remicade, is embracing medical marijuana, through co-founding ReFormation Pharmaceuticals with Professor Jagdeep Nanchahal. Specifically, ReFormation Pharmaceuticals has identified a molecule (HMGB1) that primes the body’s own stem cells to accelerate repair and regeneration following acute or chronic injury.

“As medical marijuana regulations ease, Feldmann is paving the way for a new class of cannabis derived-drugs to treat pain and other conditions. His background and expertise will be valuable as we accelerate growth in the medical marijuana pharmaceutical space and capitalize on the industry’s evolution,” says Alex Somjen, President & CEO of Resinco.

“I am pleased to chair Resinco’s Advisory Board and work with the team to advance the Second Generation of the Medical cannabis industry,” said Sir Marc Feldmann, Chairman and Founder of ReFormation Pharmaceuticals. “Through rigorous clinical trials using FDA approved practices, we intend to accelerate ReFormation’s development of cannabis treatments triggering stem cell repair, where the medical benefits are based on hard science and government regulation.”

About Resinco Capital Partners

Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies as well as medical cannabis pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile.

Website: www.resincocp.com

About ReFormation Pharmaceuticals Corp

ReFormation Pharmaceuticals Corp is a medical cannabis pharmaceutical Company headquartered in Toronto, ON, with its Research and Development team at the University of Oxford. The Company is focused on an innovative approach to repair vital organs by combining cannabinoids and an endogenous trigger of repair (HMGB1). ReFormation is based on disruptive technology which will deliver a first in-class therapeutic. The Company has identified a molecule that primes the body’s own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury. The Company’s research pipeline will deliver further IP based on composition of matter and has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. ReFormation Pharmaceuticals is led by world class scientist, CEO and Chief Science Officer, Professor Jagdeep Nanchahal, of the University of Oxford.

Website: https://www.reformationpharma.com/

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

RESINCO CAPITAL PARTNERS INC.:

Company Contact
Mr. Alexander Somjen, CEO
647-362-8998

Media Contact
Tim Gray, Account Director
KCSA Strategic Communications
Phone: 212.682.6300
Email: Resinco@KCSA.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/42665

Gunpowder Capital Corp. Receives $102,750.00 CDN in Compensation, Makes Strategic Investment, Settles Debt

Toronto, Ontario–(Newsfile Corp. – February 1, 2019) – Gunpowder Capital Corp. (CSE: GPC) (CSE: GPC.PR.A) (OTCQB: GNPWF) (FSE: YS6N) (“Gunpowder” or the “Corporation”) announced today that it had received One Hundred and Two Thousand, Seven Hundred and Fifty Dollars (“$102,750.00”) CDN in compensation for providing consulting and advisory services to its client Meryllion Resources Corp. (“Meryllion”). Gunpowder brokered a proposed Reverse Take Over (“RTO”) deal between Meryllion and Back Country Property Management (“BCPM”). BCPM is a recreational cannabis producer with operations located in the State of California. Gunpowder elected to convert the compensation that it received from Meryllion into Five Million, One Hundred and Thirty-Six Thousand, Nine Hundred and Fifty-Six (“5,136,956”) Common Shares of Meryllion Resources Corp. For more details in regards to the proposed RTO between Meryllion and BCPM that Gunpowder was instrumental in facilitating, please refer to the Meryllion’s press release dated January 30th, 2019 which can be viewed by visiting the following link:

https://www.newsfilecorp.com/company/5495/Meryllion-Resources-Corporation

The Corporation also announced today that it has participated in Advantagewon Oil Corp.’s (“AOC”) current Non-Brokered Private Placement offering. The Corporation subscribed to Seventy-Two Thousand, Five Hundred Dollars (“$72,500.00”) CDN worth of AOC Units. In total, for its $72,500.00 CDN investment into AOC the Corporation received Two Million and Seventy-One Thousand, Four Hundred and Twenty-Nine (“2,071,429”) Units. Each AOC Unit consists of One Common Share in the capital of AOC and one Common Share Purchase Warrant (a “Warrant”), with each Warrant entitling the holder thereof to purchase one Common Share of AOC at an exercise price of Six Cents (“$0.06”) CDN per Common Share for a period of 24 months from the closing of the financing, subject to accelerated expiry in the event the closing price of the AOC’s shares closes at or greater than $0.10 CDN for ten consecutive trading days.

The Corporation further announced that it had entered into a debt settlement agreement where the Corporation will issue Six Hundred Thousand (“600,000”) Common Shares of the Corporation at a deemed price of Seven and a Half Cents (“$0.075”) CDN per Common Share to settle Forty-Five Thousand Dollars (“$45,000.00”) CDN of debt due to a creditor. Due to the issuance of the 600,000 Common Shares, the Corporation now has 69,011,750 Common Shares issued and outstanding.

About Gunpowder Capital Corp.

Gunpowder Capital Corp. is a merchant bank and advisory services firm based in Toronto, Ontario, Canada. Gunpowder invests in both publicly traded and private businesses that have successful management teams and attractive economic models. Gunpowder partners with these businesses to support their growth initiatives with its proven methodology of appropriate financing and structured exits. Gunpowder offers debt financing, including mezzanine and bridge loans, equity financing and advisory services. Gunpowder is also building a portfolio of companies in which it takes a long term position and view. For more information please visit www.gunpowdercapitalcorp.com

For further information please contact:

Mr. Frank Kordy
CEO & Director
Gunpowder Capital Corp.
T: (647) 466-4037
E: frank.kordy@gunpowdercapitalcorp.com

Mr. Paul Haber
CFO
Gunpowder Capital Corp.
T: (416) 363-3833
E: paul.haber@gunpowdercapitalcorp.com

Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

– 30 –

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/42589

Resinco Capital Partners Announces Remaining Acquisition of ReFormation Pharmaceuticals Corp

ReFormation Developing First-in-Class Therapeutic to Repair Vital Organs by Combining Cannabinoids and Re-engineering a Molecule, HMGB1

Vancouver, British Columbia–(Newsfile Corp. – January 16, 2019) – Resinco Capital Partners Inc. (CSE: RIN) (OTC Pink: RSCZF) (FSE: L6V1) (the “Company” or “Resinco“) is pleased to announce that the Company has entered into a definitive agreement to acquire the remaining 51% of ReFormation Pharmaceuticals Corp, a medical cannabis company developing innovative, first-in-class therapies to repair vital organs and stem cells by combining cannabinoids and an endogenous trigger of repair. Resinco previously acquired 49% of ReFormation’s outstanding shares on October 23, 2018.

Specifically, ReFormation Pharmaceuticals has identified a molecule (HMGB1) that primes the body’s own stem cells to accelerate repair and regeneration following acute or chronic injury. Through the combination of this molecule and synthetic non-psychoactive cannabinoids they are developing a first-in-class therapy. ReFormation Pharmaceuticals is led by world-class scientist, Founder, CEO and Chief Science Officer, Professor Jagdeep Nanchahal, of the University of Oxford.

“Resinco is extremely pleased to finalize this further investment into ReFormation. ReFormation is a tremendously innovative company, with all the attributes to disrupt the medical marijuana pharmaceutical space,” says Alex Somjen, President & CEO of Resinco Capital Partners Inc. “The Global Stem Cells Market is estimated to grow to $9.03 Billion by 2023[1]  and having a company that focuses on an innovative approach to repair vital organs will be a beneficial investment as we position ourselves as a global investment company with an emphasis in ‘Second generation’ medicinal marijuana companies.”

“This acquisition will provide ReFormation with additional resources to help solve major medical unmet needs,” said Prof. Nanchahal, of ReFormation. “The repair of major tissues will be another benefit of properly researching and developing the medical activities of cannabis-based products.”

Finder’s fees will be payable in accordance with the policies of the Canadian Securities Exchange. Pursuant to the terms of the ReFormation Agreement, ReFormation will amalgamate with the Company’s wholly owned subsidiary, 1189879 B.C. Ltd., in consideration for 29,000,000 common shares of the Company. Upon completion of the transaction, Resinco’s investment in ReFormation will be held through a wholly-owned subsidiary of the Company.

About Resinco Capital Partners

Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies as well as medical cannabis pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile.

Website www.resincocp.com

About ReFormation Pharmaceuticals Corp

ReFormation Pharmaceuticals Corp is a medical cannabis pharmaceutical Company headquartered in Toronto, ON, with its Research and Development team at the University of Oxford. The Company is focused on an innovative approach to repair vital organs by combining cannabinoids and an endogenous trigger of repair (HMGB1). ReFormation is based on disruptive technology which will deliver a first in-class therapeutic. The Company has identified a molecule that primes the body’s own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury. The Company’s research pipeline will deliver further IP based on composition of matter and has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. ReFormation Pharmaceuticals is led by world class scientist, CEO and Chief Science Officer, Professor Jagdeep Nanchahal, of the University of Oxford.

Website: https://www.reformationpharma.com/

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on http://www.sedar.com

RESINCO CAPITAL PARTNERS INC.:

Company Contact
Mr. Alexander Somjen, CEO
647-362-8998

Media Contact
Tim Gray, Account Director
KCSA Strategic Communications
Phone: 212.682.6300
Email: Resinco@KCSA.com


[1] https://www.prnewswire.com/news-releases/global-stem-cells-market-research-report-2018-300708743.html

CIFSC Proposed Category Definitions for Alternative Funds

Toronto, Ontario–(Newsfile Corp. – January 10, 2019) – The CIFSC continuously monitors the categorization of investment funds, and undertakes periodic reviews of the current category definitions and structures in response to new and developing trends in the investment funds industry. The purpose of the review process is to ensure the logical, consistent categorization of investment funds and to maximize the similarity of investment strategies and risk-return profiles within each category.

Up to this point, the Alternative Strategies category has served as a blanket category for the classification of alternative funds, regardless of investment mandate or strategy. With the CSA’s introduction of Alternative Mutual Funds to NI 81-102, the CIFSC recognized a need for improved categorization of alternative funds. The CIFSC is proposing the following set of categories to segment Alternative Strategies, create a set of peer groups that are better understood by investors and advisors, and allow for meaningful fund comparisons.

The CIFSC is publishing for a 30-day comment period the following category proposals. After the 30-day comment period, the committee will review the comments and determine by private vote whether to proceed with the changes. To submit comments please use the ‘Contact’ link on the home page at www.cifsc.org or click here.

The following categories will be contained under the broad category of Alternative Funds.

Alternative Equity Focused

Funds in the Alternative Equity Focused category employ alternative strategies such as short selling or other forms of leverage. This category contains Alternative Mutual Funds that meet the requirements of NI 81-102, as well as traditional hedge funds offered by offering memorandum. The underlying securities should be primarily equities such that at least 50% of the portfolio is invested in equities. Funds in this category may use speculative and/or hedging strategies. Funds that do not issue a simplified prospectus will not be ranked with the Alternative Mutual Funds in this category.
*This category will not be ranked for the first year of its existence.

Alternative Credit Focused

Funds in the Alternative Credit Focused category employ alternative strategies such as short selling or other forms of leverage. This category contains Alternative Mutual Funds that meet the requirements of NI 81-102, as well as traditional hedge funds offered by offering memorandum. The underlying securities should be primarily fixed income such that at least 50% of the portfolio is invested in fixed income or credit related products. Funds in this category may use speculative and/or hedging strategies. Funds that do not issue a simplified prospectus will not be ranked with the Alternative Mutual Funds in this category.
*This category will not be ranked for the first year of its existence.

Alternative Multi – Strategy

Funds in the Alternative Multi – Strategy category employ alternative strategies such as short selling or other forms of leverage. This category contains Alternative Mutual Funds that meet the requirements of NI 81-102, as well as traditional hedge funds offered by offering memorandum. Funds in this category must have a stated mandate to use any, or a combination, of the alternative strategies including strategies that can be found in the other alternative categories. Funds that do not issue a prospectus will not be ranked with the Alternative Mutual Funds in this category.
*This category will not be ranked for the first year of its existence.

Alternative Market Neutral

Funds in the Alternative Market Neutral category employ alternative strategies such as short selling or other forms of leverage. This category contains Alternative Mutual Funds that meet the requirements of NI 81-102, as well as traditional hedge funds offered by offering memorandum. Funds in this category aim to reduce market exposure by pairing long and short positions. These funds generally have low correlation to market movements.
*This category will not be ranked for the first year of its existence.

Alternative Other

Funds in the Alternative Other category have a unique strategy that does not fit in to any other alternative category. This category contains Alternative Mutual Funds that meet the requirements of NI 81-102, as well as traditional hedge funds offered by offering memorandum. Funds in this category will not be ranked.

Reid Baker, CERA, ASA
Chair, Canadian Investment Funds Standards Committee
Fundata Canada Inc.
416-445-5534 x 240
reid.baker@fundata.com

Gunpowder Capital Corp. Provides Update on Acquisition of Koch & Gsell AG

Toronto, Ontario–(Newsfile Corp. – January 8, 2019) – Gunpowder Capital Corp., (CSE: GPC), (CSE: GPC.PR.A), (OTCQB: GNPWF), (FSE: YS6N), (“Gunpowder” or the “Corporation”) announced today that on Friday January 4, 2019, GPC received notice from Koch & Gsell AG (“Koch”) that Koch and Therapeutic Solutions Group TCI Ltd. (“TCI Ltd.”) are in the process of renegotiating certain aspects of their Letter of Intent (“LOI”). There is no certainty that the parties will come to mutually acceptable terms. Gunpowder will provide an update as soon as one is available.

About Gunpowder Capital Corp.

Gunpowder Capital Corp., is a merchant bank and advisory services firm based in Toronto, Ontario, Canada. Gunpowder invests in both publicly traded and private businesses that have successful management teams and attractive economic models. Gunpowder partners with these businesses to support their growth initiatives with its proven methodology of appropriate financing and structured exits. Gunpowder offers debt financing, including mezzanine and bridge loans, equity financing and advisory services. Gunpowder is also building a portfolio of companies in which it takes a long term position and view. For more information please visit www.gunpowdercapitalcorp.com.

For further information please contact:

Mr. Paul Haber
CFO
Gunpowder Capital Corp.
T: (416) 363-3833
E: paul.haber@gunpowdercapitalcorp.com

Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

– 30 –

Gunpowder Capital Corp., Declares Quarterly Dividend

Toronto, Ontario–(Newsfile Corp. – January 3, 2019) – Gunpowder Capital Corp., (CSE: GPC) (CSE: GPC.PR.A) (OTCQB: GNPWF) (FSE: YS6N) (“Gunpowder” or the “Corporation”) announced today that it has declared a dividend of $0.20 per outstanding “Class – A” and “Class – B” Preferred Share of its capital payable on, or after, February 4th, 2019 to all “Class – A” and “Class – B” Preferred Shareholders of record at the close of business on January 3rd, 2019.

About Gunpowder Capital Corp.

Gunpowder Capital Corp., is a merchant bank and advisory services firm based in Toronto, Ontario, Canada. Gunpowder invests in both publicly traded and private businesses that have successful management teams and attractive economic models. Gunpowder partners with these businesses to support their growth initiatives with its proven methodology of appropriate financing and structured exits. Gunpowder offers debt financing, including mezzanine and bridge loans, equity financing and advisory services. Gunpowder is also building a portfolio of companies in which it takes a long term position and view. For more information please visit www.gunpowdercapitalcorp.com.

For further information please contact:

Mr. Frank Kordy
CEO & Director
Gunpowder Capital Corp.
T: (647) 466-4037
E: frank.kordy@gunpowdercapitalcorp.com

Mr. Paul Haber
CFO
Gunpowder Capital Corp.
T: (416) 363-3833
E: paul.haber@gunpowdercapitalcorp.com

Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

– 30 –